By Sheeba M. | May 22, 2026
Canadian LPs Are Quietly Reshaping the Market: Tilray and CGC Lead Consolidation
Tilray and Canopy Growth just proved what skeptics have dismissed for three years: Canadian licensed producers (LPs) can scale profitably outside North America.
Tilray’s move into European distribution is the real story here. The company isn’t just selling dried flower to EU importers anymore—it’s building the supply chain itself. That means higher margins, direct customer relationships, and a runway to profitability that US MSOs can’t access due to federal banking and interstate commerce restrictions.
Meanwhile, Canopy is doubling down on cannabis 2.0 products (edibles, beverages, topicals) which have 3-4x the margin profile of dried flower. The company launched 47 new SKUs in Q1 2026 alone, many in the premium beverage category where margins exceed 65%.
The Valuation Shift
Here’s what changed: 18 months ago, Canadian LPs traded at 1.5x revenues because investors assumed commoditized flower prices forever. Today, Tilray trades at 3.2x revenues because the market is pricing in international scale and margin expansion.
Organigram is the dark horse here—the company is smaller than Tilray or Canopy but owns 40% gross margins on edibles revenue. If the market finally recognizes that cannabis 2.0 is the profit engine, Organigram becomes a sleeper acquisition target.
What This Means for US MSOs
Canadian LPs can do what US MSOs cannot: (1) operate across state lines, (2) access capital markets freely, (3) build international networks. As federal reform accelerates (watch the SAFER Act in Congress), Canadian LPs will have a head start on vertical integration across North America. Expect consolidation announcements by Q3 2026.
Sources
- SEC Edgar — Tilray and Canopy Q1 2026 filings
- Bloomberg — Cannabis M&A and international expansion coverage
- SEDAR — Canadian disclosure system
Track cannabis stocks with the Weedstock Real-Time Tracker